Prognostic Role of Serum Albumin Level in Patients with Lymphoma Undergoing Autologous Stem Cell Transplantation

12 October 2021 : Original article

Chengxin Luo^12CDE, Qingrong Li^12B, Xi Li

^3B, Guixian Wu^12B, Xiangtao Huang^12B, Yali Zhang^12B, Yanni Ma^12B, Mingling Xie^12B, Yanni Sun

^12B, Yarui Huang^12B, Zhen Huang^12B, Shuangnian Xu^12AEG*, Jieping Chen^12AEG

DOI: 10.12659/AOT.933365

Ann Transplant 2021; 26:e933365

Background Material and Methods Results Discussion Conclusions References

Related articles Order reprints Share article Share by email

View HTML version

Table 2 Results of univariate and multivariate Cox regression analyses for progression-free survival.

Characteristics	Univariate analysis		Multivariate analysis
Characteristics	HR (95%CI)	P	HR (95%CI)	P
Male	1.99 (0.97–4.09)	0.061
Age >60	3.06 (1.34–6.97)	0.008^*	2.92 (1.27–6.71)	0.012^*
BMI <18.5	0.49 (0.12–2.05)	0.331
Lymphoma subtype
B-NHL	1.00
T-NHL	1.34 (0.55–3.25)	0.519
NK/T-NHL	1.80 (0.54–5.99)	0.339
HL	0.56 (0.17–1.83)	0.334
ECOG PS 2–3	1.33 (0.71–2.52)	0.376
Ann Arbor stage III–IV	0.95 (0.44–2.07)	0.901
B symptoms	0.98 (0.51–1.89)	0.947
IPI risk
Low	1.00
Low-intermediate	1.11 (0.51–2.45)	0.793
High-intermediate	0.99 (0.38–2.62)	0.987
High	1.99 (0.82–4.80)	0.127
LDH elevation (>240 U/L)	1.72 (0.92–3.23)	0.090
Bone marrow involvement	1.64 (0.64–4.22)	0.304
Prior regimens	1.07 (0.71–1.6)	0.744
<5	1.00
5–10	0.87 (0.41–1.84)	0.708
≥10	1.77 (0.54–5.88)	0.348
PR or NR	1.70 (0.89–3.24)	0.107
Disease duration	1.00 (0.98–1.02)	0.953
Albumin <37 g/L	3.29 (1.60–6.79)	0.001^*	3.19 (1.54–6.63)	0.002^*
TP <60 g/L	2.25 (1.07–4.76)	0.033^*
Globulin level	0.95 (0.88–1.02)	0.178
Albumin/globulin ratio	0.87 (0.33–2.28)	0.781
Conditioning regimen
BEAM	1.00
BEAC	1.35 (0.50–3.67)	0.551
CBV	1.12 (0.41–3.07)	0.834
CHOP-like	1.21 (0.43–3.40)	0.712
Dose of infused mononuclear cells	0.96 (0.83–1.11)	0.599
Maintenance therapy	1.20 (0.63–2.31)	0.575
^*

Back to the Article